'Alarming' underuse of trastuzumab in breast cancer

'Alarming' underuse of trastuzumab in breast cancer

Nearly one-half of all eligible patients aged 65 years and older with Stage I–III breast cancer do not receive trastuzumab-based therapy, which has been proven effective. In a study published in the Journal of Clinical Oncology, researchers found that

(Visited 3 times, 1 visits today)
2
Like
Save

Comments

Write a comment